Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 210

1.

SYK inhibition and response prediction in diffuse large B-cell lymphoma.

Cheng S, Coffey G, Zhang XH, Shaknovich R, Song Z, Lu P, Pandey A, Melnick AM, Sinha U, Wang YL.

Blood. 2011 Dec 8;118(24):6342-52. doi: 10.1182/blood-2011-02-333773. Epub 2011 Oct 24.

2.

Tyrosine kinase inhibition in diffuse large B-cell lymphoma: molecular basis for antitumor activity and drug resistance of dasatinib.

Yang C, Lu P, Lee FY, Chadburn A, Barrientos JC, Leonard JP, Ye F, Zhang D, Knowles DM, Wang YL.

Leukemia. 2008 Sep;22(9):1755-66. doi: 10.1038/leu.2008.163. Epub 2008 Jul 3.

PMID:
18596745
3.

FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.

Szydlowski M, Kiliszek P, Sewastianik T, Jablonska E, Bialopiotrowicz E, Gorniak P, Polak A, Markowicz S, Nowak E, Grygorowicz MA, Prochorec-Sobieszek M, Szumera-Cieckiewicz A, Malenda A, Lech-Maranda E, Warzocha K, Juszczynski P.

Blood. 2016 Feb 11;127(6):739-48. doi: 10.1182/blood-2015-06-654111. Epub 2015 Nov 19.

4.

Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma.

Ma J, Xing W, Coffey G, Dresser K, Lu K, Guo A, Raca G, Pandey A, Conley P, Yu H, Wang YL.

Oncotarget. 2015 Dec 22;6(41):43881-96. doi: 10.18632/oncotarget.6316.

5.

The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphoma.

Lyu MA, Sung B, Cheung LH, Marks JW, Aggarwal BB, Aguiar RC, Rosenblum MG.

Biochem Pharmacol. 2010 Nov 1;80(9):1335-42. doi: 10.1016/j.bcp.2010.07.017. Epub 2010 Jul 21.

PMID:
20654581
6.

Quantitative immunofluorescence reveals the signature of active B-cell receptor signaling in diffuse large B-cell lymphoma.

Bogusz AM, Baxter RH, Currie T, Sinha P, Sohani AR, Kutok JL, Rodig SJ.

Clin Cancer Res. 2012 Nov 15;18(22):6122-35. doi: 10.1158/1078-0432.CCR-12-0397. Epub 2012 Sep 10.

7.

SYK-dependent tonic B-cell receptor signaling is a rational treatment target in diffuse large B-cell lymphoma.

Chen L, Monti S, Juszczynski P, Daley J, Chen W, Witzig TE, Habermann TM, Kutok JL, Shipp MA.

Blood. 2008 Feb 15;111(4):2230-7. Epub 2007 Nov 15.

8.

Spleen tyrosine kinase inhibition prevents chemokine- and integrin-mediated stromal protective effects in chronic lymphocytic leukemia.

Buchner M, Baer C, Prinz G, Dierks C, Burger M, Zenz T, Stilgenbauer S, Jumaa H, Veelken H, Zirlik K.

Blood. 2010 Jun 3;115(22):4497-506. doi: 10.1182/blood-2009-07-233692. Epub 2010 Mar 24.

9.

Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth.

Gururajan M, Dasu T, Shahidain S, Jennings CD, Robertson DA, Rangnekar VM, Bondada S.

J Immunol. 2007 Jan 1;178(1):111-21.

10.

Rational combined targeting of phosphodiesterase 4B and SYK in DLBCL.

Kim SW, Rai D, McKeller MR, Aguiar RC.

Blood. 2009 Jun 11;113(24):6153-60. doi: 10.1182/blood-2009-02-206128. Epub 2009 Apr 15.

11.

Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells.

Gioia R, Leroy C, Drullion C, Lagarde V, Etienne G, Dulucq S, Lippert E, Roche S, Mahon FX, Pasquet JM.

Blood. 2011 Aug 25;118(8):2211-21. doi: 10.1182/blood-2010-10-313692. Epub 2011 Jul 5.

12.

Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.

Petrich AM, Leshchenko V, Kuo PY, Xia B, Thirukonda VK, Ulahannan N, Gordon S, Fazzari MJ, Ye BH, Sparano JA, Parekh S.

Clin Cancer Res. 2012 May 1;18(9):2534-44. doi: 10.1158/1078-0432.CCR-11-1407. Epub 2012 Feb 14.

13.

SYK inhibition modulates distinct PI3K/AKT- dependent survival pathways and cholesterol biosynthesis in diffuse large B cell lymphomas.

Chen L, Monti S, Juszczynski P, Ouyang J, Chapuy B, Neuberg D, Doench JG, Bogusz AM, Habermann TM, Dogan A, Witzig TE, Kutok JL, Rodig SJ, Golub T, Shipp MA.

Cancer Cell. 2013 Jun 10;23(6):826-38. doi: 10.1016/j.ccr.2013.05.002.

14.

Distinct patterns of B-cell receptor signaling in non-Hodgkin lymphomas identified by single-cell profiling.

Myklebust JH, Brody J, Kohrt HE, Kolstad A, Czerwinski DK, Wälchli S, Green MR, Trøen G, Liestøl K, Beiske K, Houot R, Delabie J, Alizadeh AA, Irish JM, Levy R.

Blood. 2017 Feb 9;129(6):759-770. doi: 10.1182/blood-2016-05-718494. Epub 2016 Dec 23.

15.

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA.

Blood. 2010 Apr 1;115(13):2578-85. doi: 10.1182/blood-2009-08-236471. Epub 2009 Nov 17.

16.

Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma.

Goldstein RL, Yang SN, Taldone T, Chang B, Gerecitano J, Elenitoba-Johnson K, Shaknovich R, Tam W, Leonard JP, Chiosis G, Cerchietti L, Melnick A.

J Clin Invest. 2015 Nov 3;125(12):4559-71. doi: 10.1172/JCI80714.

17.

The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression.

Baudot AD, Jeandel PY, Mouska X, Maurer U, Tartare-Deckert S, Raynaud SD, Cassuto JP, Ticchioni M, Deckert M.

Oncogene. 2009 Sep 17;28(37):3261-73. doi: 10.1038/onc.2009.179. Epub 2009 Jul 6.

PMID:
19581935
18.

Syk-dependent mTOR activation in follicular lymphoma cells.

Leseux L, Hamdi SM, Al Saati T, Capilla F, Recher C, Laurent G, Bezombes C.

Blood. 2006 Dec 15;108(13):4156-62. Epub 2006 Aug 15.

19.

Syk-induced phosphatidylinositol-3-kinase activation in Epstein-Barr virus posttransplant lymphoproliferative disorder.

Hatton O, Lambert SL, Phillips LK, Vaysberg M, Natkunam Y, Esquivel CO, Krams SM, Martinez OM.

Am J Transplant. 2013 Apr;13(4):883-890. doi: 10.1111/ajt.12137. Epub 2013 Feb 7.

20.

SYK regulates mTOR signaling in AML.

Carnevale J, Ross L, Puissant A, Banerji V, Stone RM, DeAngelo DJ, Ross KN, Stegmaier K.

Leukemia. 2013 Nov;27(11):2118-28. doi: 10.1038/leu.2013.89. Epub 2013 Mar 28.

Supplemental Content

Support Center